News

Meitheal Pharmaceuticals Announces Findings from Collaborative Research Study with Premier Inc. Evaluating Anticoagulant Treatment of COVID-19 Patients

Customer Notification Recall Communication Letter

Urgent: Glycopyrrolate Injection, USP 4mg per 20mL RECALL

NKF and Meitheal Announce Dr. Jiali Luo as General Manager of New Biopharmaceutical Business

Meitheal Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Cisatracurium Besylate Injection, USP 10mg per 5mL Due to Mislabeling

Meitheal Pharmaceuticals Announces Launch of Enoxaparin Sodium Injection, USP in the United States 

CORONAVIRUS STATEMENT

Meitheal Pharmaceuticals Announces FDA Approval of Additional Manufacturing Capacity and Future Facility Expansion Plans for Production of Heparin Sodium Injection, USP

Meitheal Pharmaceuticals Announces FDA Approval of Enoxaparin Sodium Injection, USP in the United States 

Meitheal Pharmaceuticals Announces Completion of Majority Stake Investment from Nanjing King-Friend Biochemical Pharmaceutical Company